# IDEAYA Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/IDEAYA Biosciences, Inc.). ## Overview IDEAYA Biosciences is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies matched to specific molecular alterations. Its pipeline centers on small-molecule programs, synthetic lethality, and antibody-drug conjugates, with development guided by companion diagnostics and biomarker selection. ## Products & services • Darovasertib for uveal melanoma • Synthetic lethality oncology programs • Antibody-drug conjugate (ADC) programs • MTAP pathway targeted therapies • Biomarker-driven companion diagnostics collaboration - **Darovasertib / uveal melanoma** (10%) — Clinical development of darovasertib for uveal melanoma, including combination and registrational studies. - **ADC and DDR combinations** (25%) — Antibody-drug conjugate and DNA damage response combination programs in molecularly defined solid tumors. - **MTAP pathway programs** (20%) — Targeted therapies aimed at MTAP-deleted cancers and related synthetic lethality biology. - **Next-generation therapies** (20%) — Earlier-stage discovery and development programs beyond the current lead assets. - **Collaboration revenue and diagnostics enablement** (25%) — Revenue from partnered R&D, licensing, milestones, and diagnostic-enabling activities. - Darovasertib, including combinations for uveal melanoma - Synthetic lethality small-molecule oncology programs - Antibody-drug conjugate (ADC) pipeline candidates - MTAP pathway targeted therapies - Biomarker and companion diagnostic development - Clinical-stage precision medicine combinations ## Customers IDEAYA does not yet sell approved products; its current counterparties are pharmaceutical partners, diagnostic companies, and clinical investigators rather than end patients. If approved, its medicines would be used by oncologists treating molecularly defined cancer populations, with commercialization initially planned in the United States and selectively abroad. The company also relies on diagnostic partners to identify eligible patients and on CMOs to manufacture clinical and future commercial supply. - **Pharmaceutical collaboration partners** (primary) — Partners such as GSK, Servier, Pfizer, Gilead, Biocytogen, and Hengrui support development, licensing, supply, or commercialization of specific programs. - **Diagnostic and biomarker partners** (primary) — Companies like Foundation Medicine, Guardant Health, and Tempus help identify patients most likely to benefit from IDEAYA's therapies. - **Clinical investigators and trial sites** (primary) — Academic and community oncology centers enroll patients into biomarker-selected studies and registrational trials. - **Future oncology prescribers** (secondary) — Specialist oncologists would prescribe approved products for defined cancer subtypes if the pipeline reaches commercialization. - **Contract manufacturing organizations** (secondary) — CMOs manufacture API, drug product, and related supply for preclinical, clinical, and future commercial use. - Oncologists treating biomarker-selected solid tumor patients - Pharma partners funding or co-developing pipeline programs - Diagnostic firms enabling patient selection and trial enrollment - Clinical trial sites enrolling molecularly defined cancer cohorts - CMOs supplying API, drug product, packaging, and distribution ## Geography IDEAYA is headquartered in the United States and currently expects to commercialize any approved medicines first in the U.S., with potential expansion into Europe and other selected foreign markets. Outside the U.S., darovasertib commercialization is licensed to Servier, which makes international reach partner-dependent rather than fully owned. The company also depends on global diagnostic, manufacturing, and clinical trial networks to support its precision-medicine development model. - United States is the planned first commercial market - Europe is a potential expansion market for future products - Servier holds ex-U.S. rights to darovasertib worldwide - Clinical and diagnostic partners are globally distributed - Manufacturing is outsourced to third-party CMOs ## Strategy IDEAYA's strategy is to build a precision oncology pipeline around molecularly defined cancers where biomarker selection can improve response rates and trial efficiency. It is prioritizing darovasertib, ADC/DDR combinations, and MTAP pathway programs while using partnerships to share development risk, access diagnostics, and extend commercialization reach. The company also plans to build a U.S. sales force only if and when products are approved, while relying on collaborators outside the U.S. where appropriate. - **Advance darovasertib in uveal melanoma** (short-term) — This is the most advanced asset and a potential first commercial product. - **Progress ADC, DDR, and MTAP pipeline programs** (medium-term) — Diversifies the pipeline and creates multiple shots on goal in precision oncology. - **Expand biomarker and diagnostic capabilities** (medium-term) — Patient selection is central to the company's precision-medicine thesis and trial success. - **Use partnerships for ex-U.S. commercialization and funding** (short-term) — Partnerships reduce capital needs and provide external validation for programs. - Focus on biomarker-selected oncology to improve clinical success odds - Advance darovasertib through registrational and combination studies - Develop synthetic lethality and ADC programs across solid tumors - Use diagnostics partnerships to refine patient selection - Leverage licensing and collaboration deals to fund development ## Risks IDEAYA is a clinical-stage biotech with no approved products, so its value depends on successful trials, regulatory approvals, and eventual commercialization. The company also faces substantial financing, competition, and execution risk because it must fund long development cycles, outsource manufacturing, and build commercial capabilities if programs succeed. Precision oncology adds diagnostic and reimbursement risk, since therapies must be matched to the right patients and payors must accept the value proposition. - **Clinical development failure** [high] — Pipeline value depends on demonstrating safety and efficacy in biomarker-defined cancers. - **Financing risk** [high] — The company has significant losses and will likely need additional capital to fund development. - **Competition from larger oncology companies** [medium] — Rivals may develop similar targeted therapies faster or with greater resources. - **Commercialization and reimbursement risk** [medium] — Even approved products may face payer resistance or limited reimbursement in niche indications. - **Manufacturing and supply-chain dependence** [medium] — The company relies on third-party CMOs for API, drug product, and diagnostics supply. - No approved products, so revenue depends on future clinical success - Clinical trial failure or delays could impair the entire pipeline - Heavy competition from larger pharma and biotech companies - Need for additional capital if collaboration funding is insufficient - Commercialization and reimbursement risk for biomarker-selected therapies ## Accounting The company recognizes collaboration revenue from licenses, milestones, and R&D services, with some amounts recognized at a point in time and others over time as services are performed. Because revenue is driven by partner milestones and the completion of performance obligations, reported revenue can fluctuate significantly from period to period and is not comparable to product-company revenue. Investors should also watch estimates around contract assets/liabilities, stock-based compensation, and the valuation of marketable securities held as part of its cash runway. - **Collaboration revenue recognition** — Can cause large quarter-to-quarter swings in reported revenue - **Contract assets and liabilities** — Affects balance sheet presentation and revenue timing - **Stock-based compensation** — Impacts reported losses and non-cash expense trends - **Marketable securities valuation** — Fair value changes can affect other comprehensive income and liquidity disclosure - Collaboration revenue depends on milestone timing and service completion - Point-in-time license revenue can create lumpy quarterly results - Over-time R&D service revenue depends on performance obligation progress - No product revenue yet, so reported revenue is partnership-driven - Cash and marketable securities valuation affects liquidity disclosure --- *Last updated: 2026-04-28T20:15:31.859168+00:00*